A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar

NCT ID: NCT05434897

Last Updated: 2022-07-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-31
• Study Completion Date: 2023-11-30

Brief Summary

A randomized, double-blind, placebo self-controlled phase I/II clinical study to evaluate the safety, tolerability and preventive efficacy of different doses of AK3280 cream （AK3287 ） after cicatrectomy in Patients with Hypertrophic Scar in China.

Detailed Description

Thirty patients with hypertrophic scar who will scheduled for cicatrectomy and meet the all inclusion criteria and none of exclusion criteria will participate in this study. There will be 3 cohorts for 2%, 4%, 8% doses of AK3287 （AK3280 cream） in turn, and 10 participants in each cohort. Participants in every cohort will receive cicatrectomy on day -5, and their incisions will be divided into 3 parts with equal length after length measurement on day 1, named S1, S2, S3. S1 is proximal, and S3 is distal. AK3280 cream （AK3287 ） or placebo will topically administrated to S1 or S3 randomly, twice a day (BID). In this study, S1 and S3 paired, placebo self-control design will be adopted.

The study includes a 4-week screening period, a 12-week drug observation period, and a 2-week safety follow-up period.

Conditions

Hypertrophic Scar

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

2% dose AK3280 cream

After the 4-week screening period, Eligible subjects will be administered daily 2% dose AK3280 cream b.i.d. for 12weeks.

Group Type: EXPERIMENTAL

AK3280 Cream

Intervention Type: DRUG

Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

4% dose AK3280 cream

After the 4-week screening period, Eligible subjects will be administered daily 4% dose AK3280 cream b.i.d. for 12weeks.

Group Type: EXPERIMENTAL

AK3280 Cream

Intervention Type: DRUG

Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

8% dose AK3280 cream

After the 4-week screening period, Eligible subjects will be administered daily 8% dose AK3280 cream b.i.d. for 12weeks.

Group Type: EXPERIMENTAL

AK3280 Cream

Intervention Type: DRUG

Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

Placebo cream

The same subject will be randomized to receive topical administration of AK3280 cream or placebo cream at S1 and S3, respectively.

Group Type: ACTIVE_COMPARATOR

Placebo cream

Intervention Type: DRUG

Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use

Interventions

AK3280 Cream

Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use

Intervention Type: DRUG

Placebo cream

Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use

Intervention Type: DRUG

Other Intervention Names

AK3287

Eligibility Criteria

Inclusion Criteria

• 1) Patients who sign informed consent before participating in the study.
• 2) Patients aged between 18 and 60 (including 18 and 60).
• 3)Patients who understand and be willing to follow the study procedure and be able to complete the whole process of the study.
• 4) Patients with visible hypertrophic scars in any location other than the face and anterior middle and upper neck caused by trauma or surgery and planned for surgical treatment.
• 5) Patients with postoperative scar length ≥ 6 cm, and preoperative scar length ≥4cm.
• 6) Women of childbearing age should have negative serum pregnancy test during screening period and on study day 1.

Exclusion Criteria

• 1) Patients who were systematically treated or topically treated with corticosteroids or immunosuppressants during the 30 days prior to the screening period;
• 2) Patients who accepted systematically chemotherapy during 30 days prior to the screening period;
• 3) Patients whose hypertrophic scars are being locally infected, or with sepsis;
• 4) Hypertrophic scar patients with potential keloid trend or keloid history;
• 5) Patients with autoimmune diseases or immune insufficiency or defects
• 6)Patient with uncontrolled diabetes - HbA1c (glycosylated hemoglobin A1c) ≥ 8% ，with peripheral neuropathy, peripheral arterial atresia, or other vascular diseases;
• 7) Patients with abnormal anticoagulation or coagulation function;
• 8) Patients with atrophic skin diseases, rheumatism or hemopathy ;
• 9) Patients with abnormal liver and kidney function: I. AST (Aspartate Transaminase) or ALT (Alanine Transaminase) > the upper limit of normal, and total bilirubin > the upper limit of normal; Ii. AST or ALT≥1.5 times of the upper limit of normal; Iii. Creatinine clearance rate< 60mL/ min ;
• 10) Patients with infectious diseases such as positive antibody of HBV (hepatitis B virus) , HCV (hepatitis B virus), HIV (human immunodeficiency virus) or syphilis;
• 11) The patients or their family have a history of hypersensitivity or allergies to multiple substances, or serious atopic dermatitis, or are not suitable for participate this study by investigator's judgment;
• 12) Patients who are currently or possibly suffering from malignant tumors;
• 13) Patients with definite diagnosis of mental illness with irregular medication;
• 14) Patients received any treatment that may affect wound healing, cicatrization, hemostasis or anti-coagulation, possible interactions with investigational drug within 30 days prior to randomization;
• 15) The investigators judge that patients have safety risk, or cannot complete this study or collect all blood concentration because of patient's general condition, comorbidity or medical history, or abnormal physical examination/vital signs/laboratory tests/electrocardiogram;
• 16) Patients who have received scar ablation or X-ray therapy within the past 6 months;
• 17) Patients have participated in other clinical trials of medicine or devices within 30 days prior to the screening period;
• 18) Pregnant or lactating women;
• 19) Women and men of reproductive age who are not willing to use highly effective contraception during the study period and at least 3 months after the last administration.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jihong Liu

Role: STUDY_DIRECTOR

Medical Director

Yan Wu

Role: STUDY_CHAIR

Chief Medical Officer

Locations

Shanghai Ninth People's Hospital,Shanghal JiaoTong University School of Medicine

Shanghai, Shanghai Municipality, China

Countries

China

Central Contacts

Minyan Guo

Role: CONTACT

nora.guo@arkbiosciences.com

86-13651919464

Other Identifiers

AK3287-2001

Identifier Type: -

Identifier Source: org_study_id